Belite Bio raises $15 million in registered direct offering

Published 07/08/2025, 13:18
Belite Bio raises $15 million in registered direct offering

SAN DIEGO - Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on retinal degenerative diseases with a market capitalization of $2.2 billion, announced Thursday it has entered into a securities purchase agreement with a single large existing institutional shareholder. According to InvestingPro data, the company maintains a strong financial position with a current ratio of nearly 26x, indicating robust liquidity.

The registered direct offering consists of 230,770 American Depositary Shares (ADSs) and warrants to purchase an additional 230,770 ADSs at $65 per ADS and accompanying warrant. The transaction is expected to generate approximately $15 million in gross proceeds before deducting offering expenses. With analyst price targets ranging from $80 to $110, according to InvestingPro, the stock shows potential upside from current levels.

The five-year warrants could potentially provide an additional $15 million if exercised. The offering is expected to close on or about Friday, subject to customary closing conditions.

Belite Bio plans to use the net proceeds for working capital and general corporate purposes, according to the press release statement. Titan Partners Group, a division of American Capital Partners, is serving as the sole placement agent for the offering.

The offering is being conducted under a shelf registration statement on Form F-3 previously filed with the U.S. Securities and Exchange Commission and declared effective on January 27, 2025.

Belite Bio focuses on developing therapeutics for retinal degenerative eye diseases with significant unmet medical needs, including Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration, as well as specific metabolic diseases. The company’s next earnings report is scheduled for August 11, 2025. For deeper insights into BLTE’s financial health, growth prospects, and detailed analysis, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

In other recent news, Belite Bio Inc reported a narrower-than-expected loss for the first quarter of 2025, with earnings per share at -$0.27, surpassing analysts’ forecast of -$0.37. The company also achieved a significant regulatory milestone as the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its drug candidate, Tinlarebant, for the treatment of Stargardt disease. This designation is based on promising interim results from the ongoing Phase 3 DRAGON trial and is expected to expedite the drug’s development and review process. Additionally, Belite Bio successfully completed enrollment for its Phase 3 PHOENIX trial, involving 500 subjects across multiple countries. Analyst firms such as H.C. Wainwright and Benchmark have reiterated Buy ratings on the company’s stock, with price targets set at $100 and $80, respectively. Cantor Fitzgerald also maintains an Overweight rating, expressing optimism about Belite Bio’s development of PRGN-2012 for Recurrent Respiratory Papillomatosis. The company’s financial position appears strong, with four years’ worth of cash reserves, allowing it to withstand potential market disruptions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.